Trials / Completed
CompletedNCT03950882
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Poxel SA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the pharmacokinetics of PXL770 after 4 weeks of treatment.
Detailed description
The study will be performed in subjects with Nonalcoholic Fatty Liver Disease. The primary endpoint will be the assessment of PXL770 exposure in plasma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PXL770 | Oral capsule |
| DRUG | Placebo | Oral capsule |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2020-03-29
- Completion
- 2020-03-31
- First posted
- 2019-05-15
- Last updated
- 2021-06-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03950882. Inclusion in this directory is not an endorsement.